Dorsey Wright & Associates reduced its stake in shares of Relx Plc (NYSE:RELX – Free Report) by 22.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,028 shares of the technology company’s stock after selling 18,231 shares during the period. Dorsey Wright & Associates’ holdings in Relx were worth $2,863,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in RELX. CENTRAL TRUST Co grew its stake in Relx by 1,290.2% during the 4th quarter. CENTRAL TRUST Co now owns 570 shares of the technology company’s stock valued at $26,000 after purchasing an additional 529 shares during the last quarter. Versant Capital Management Inc purchased a new stake in Relx in the fourth quarter valued at approximately $31,000. Sierra Ocean LLC acquired a new position in Relx in the 4th quarter worth approximately $43,000. Brown Brothers Harriman & Co. raised its position in Relx by 218.5% during the 4th quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company’s stock worth $44,000 after buying an additional 662 shares during the last quarter. Finally, Private Trust Co. NA lifted its stake in Relx by 119.9% during the 3rd quarter. Private Trust Co. NA now owns 1,038 shares of the technology company’s stock valued at $49,000 after acquiring an additional 566 shares during the period. 15.02% of the stock is owned by hedge funds and other institutional investors.
Relx Price Performance
NYSE:RELX opened at $50.21 on Friday. Relx Plc has a 12 month low of $40.25 and a 12 month high of $51.99. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46. The stock has a 50 day moving average of $49.48 and a two-hundred day moving average of $47.82. The firm has a market cap of $93.18 billion, a P/E ratio of 26.99, a price-to-earnings-growth ratio of 2.73 and a beta of 0.90.
Relx Increases Dividend
Analyst Ratings Changes
Several equities research analysts have commented on the stock. StockNews.com lowered shares of Relx from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Redburn Atlantic began coverage on Relx in a report on Wednesday, January 8th. They set a “buy” rating on the stock. Barclays upgraded Relx from an “equal weight” rating to an “overweight” rating in a research report on Friday, March 14th. Finally, The Goldman Sachs Group began coverage on Relx in a research report on Wednesday. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.
View Our Latest Analysis on Relx
Relx Company Profile
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Featured Articles
- Five stocks we like better than Relx
- Dividend Payout Ratio Calculator
- MarketBeat Week in Review – 03/24 – 03/28
- What Is WallStreetBets and What Stocks Are They Targeting?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Pros And Cons Of Monthly Dividend Stocks
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.